한국콜마 회사 알아보기

✅ Kolmar Korea Company Analysis

1. Company Overview

Category	Details
Company Name	Kolmar Korea Co., Ltd.
Established	1990
Headquarters	Seocho-gu, Seoul, South Korea
CEO	Hwa-Young Jung (정화영)
Industry	OEM/ODM manufacturing for cosmetics, pharmaceuticals, and health supplements
Stock Info	KOSDAQ listed (Ticker: 161890)
Website	www.kolmar.co.kr

2. Business Structure

2.1 Cosmetics Division

• OEM/ODM services for skincare, makeup, sun care
• Clients include L’Oréal, Lancôme, Innisfree, etc.
• Global R&D and manufacturing facilities

2.2 Pharmaceutical Division

• Prescription and OTC drug manufacturing
• Focus on contract manufacturing (CMO)

2.3 Health Supplements Division (Kolmar BNH)

• ODM specialist for functional foods
• Famous for "HemoHIM" supplement sold by Atomy
• End-to-end service from R&D to packaging

3. Key Financials (2023)

📊 Consolidated Performance

Metric	Amount (KRW)	YoY Growth
Revenue	₩1.348 trillion	+10.6%
Operating Profit	₩79.8 billion	+36.1%
Net Profit	₩49.7 billion	+39.3%

Segment Breakdown:

• Cosmetics: ₩620 billion
• Pharmaceuticals: ₩350 billion
• Health Supplements: ₩370 billion

*Kolmar BNH is a listed subsidiary with 50%+ ownership by Kolmar Korea.

4. Key Strengths

4.1 Global R&D Capabilities

• 12+ global R&D hubs
• Advanced cosmetic, biotech, and skincare technologies

4.2 Stable Client Base

• Partners with global brands: Amorepacific, LG H&H, Chanel, etc.
• Long-term supply of HemoHIM to Atomy

4.3 ESG & Sustainability

• Green manufacturing and recyclable packaging
• Strong focus on CSR and ethics

5. Recent Developments (2024–2025)

• Expansion of U.S. operations and Chinese marketing
• Launched AI-powered cosmetic R&D tools
• Growth in HemoHIM sales and functional ingredient R&D

6. Future Outlook

Area	Outlook
Cosmetics ODM	Growth driven by K-beauty popularity worldwide
Health Supplements	High demand for premium, science-based ingredients
Pharmaceuticals	CMO growth supported by aging society

7. Summary

Kolmar Korea is a leading Korean OEM/ODM manufacturer in cosmetics, pharmaceuticals, and health supplements. Backed by a global client base and R&D infrastructure, it is expanding rapidly in international markets, with 2023 revenues exceeding ₩1.3 trillion. Its strengths in innovation, sustainability, and client trust make it a top player in its field.